Beyond Air AAQS 2024
Beyond Air AAQS
5
Ticker
XAIR
ISIN
US08862L1035
WKN
A2PNGL
Beyond Air ima trenutni AAQS od 5. Visoki AAQS može se smatrati pozitivnim pokazateljem da se poduzeće uspješno razvija. Investitori mogu očekivati da je poduzeće na dobrom putu da ostvaruje dobit. S druge strane, važno je usporediti AAQS dionice Beyond Air s ostvarenim dobitima i drugim poduzećima iste industrije. Visoki AAQS nije apsolutna garancija za pozitivnu budućnost. Samo tako možemo dobiti potpunu sliku o performansi poduzeća. Da bi bolje procijenili razvoj poduzeća, važno je usporediti AAQS s drugim poduzećima iste industrije. Generalno, investitori bi uvijek trebali razmatrati AAQS poduzeća u kontekstu s drugim financijskim pokazateljima poput dobiti, EBIT-a, Cash Flow-a i drugih kako bi donijeli obrazloženu investicijsku odluku.
Beyond Air Aktienanalyse
Što radi Beyond Air?
Beyond Air Inc is a global company specializing in the development and production of medical products. The company was founded in 2011 by Steven Lisi, who is also the current CEO (Chief Executive Officer). History Beyond Air Inc was founded to develop new treatment options for patients with respiratory diseases. The company's focus is on researching and developing technologies that can be used to combat severe lung diseases. In 2014, Beyond Air Inc merged with NitricGen Inc, a provider of nitric oxide systems for the healthcare industry. This merger allowed Beyond Air Inc to expand its portfolio and enhance its offering of medical products. Business Model Beyond Air is a pharmaceutical company focused on respiratory diseases. The company follows a licensing-based business model, licensing its technologies and products to partner licensees to ensure improved marketing and widespread availability of its products. Beyond Air also has its own marketing and sales department, which sells directly to medical facilities. This highlights the need for licenses to support independent distribution in order to make Beyond Air's products accessible everywhere. Divisions Beyond Air operates in two main business areas. The first is the "Medical Grade Nitric Oxide" division, where the company develops novel technologies for the treatment of respiratory diseases. The second is the "Nasal Nitric Oxide" division, which has developed a patented device for nasal breathing enhancement in children. Products One of Beyond Air's key innovations is the medical device LungFit™, which is used directly at the patient's bedside and delivers medical nitric oxide into the airways. LungFit™ is an advanced medical device used for the treatment of patients with severe respiratory diseases such as bronchospasm, COPD (Chronic Obstructive Pulmonary Disease), and ARDS (Acute Respiratory Distress Syndrome). Additionally, Beyond Air also offers a patented nasal breathing device for children. This device increases nasal flow and allows for better breathing in children with colds or allergic upper respiratory tract conditions. Conclusion Beyond Air is a globally operating company focusing on the development of medical products for patients with respiratory diseases. The company follows a licensing-based business model to make its products accessible through partner licensees. Beyond Air offers innovative and advanced medical devices, including the LungFit™ system and a patented nasal breathing device for children. Beyond Air ist eines der beliebtesten Unternehmen auf Eulerpool.com.Česta pitanja o Beyond Air dionici
Aktiensparpläne nude atraktivnu mogućnost za investitore za dugoročno stvaranje imovine. Jedna od glavnih prednosti je tzv. efekt prosječenja troškova: investirajući redovito fiksni iznos u dionice ili dioničke fondove, automatski se kupuje više udjela kada su cijene niske, a manje kada su visoke. To može dovesti do povoljnijeg prosječnog cijene po udjelu tijekom vremena. Osim toga, Aktiensparpläne omogućavaju i malim investitorima pristup skupim dionicama, jer mogu sudjelovati već s malim iznosima. Redovita investicija također promiče discipliniranu strategiju ulaganja i pomaže izbjeći emocionalne odluke, poput impulzivne kupnje ili prodaje. Pored toga, investitori profitiraju od potencijalnog povećanja vrijednosti dionica kao i od isplata dividendi koje mogu biti reinvestirane, što pojačava učinak kamatnog kamata i time rast uloženog kapitala.
Andere Kennzahlen von Beyond Air
Naša analiza dionica Beyond Air Prihod uključuje važne financijske pokazatelje kao što su prihod, dobit, P/E omjer, P/S omjer, EBIT, kao i informacije o dividendi. Također, razmatramo aspekte poput dionica, tržišne kapitalizacije, dugova, vlastitog kapitala i obveza Beyond Air Prihod. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama nudimo opsežne analize:
